A Registry Study on Shuxuetong (a Chinese Medicine Injection) Used in Twenty Hospitals
NCT ID: NCT01508403
Last Updated: 2013-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30000 participants
OBSERVATIONAL
2012-01-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
NCT04415164
Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE
NCT04275349
Xingnaojing for Mild-to-severe Acute Ischemic Stroke
NCT04150835
Clinical Evaluation of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke
NCT04200781
Study on the Clinical Efficacy of Chinese Medicine Treatment of Sequelae of Apoplexy
NCT03077984
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is well known that Chinese medicine injection is just limited in mainland China, which also be accepted by China health care system.
However, more and more adverse events or adverse drug reaction have been reported in recent years in the form of case report.
In order to improving monitoring adverse events or adverse drug reaction of Chinese medicine injection in hospital, registry study will be introduced in this area.
To calculate the incidence of adverse events or adverse drug reaction is one of the main aims for this study.
According to the 'rule of three', 30,000 cases need to be registered at least.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shuxuetong injection
a cohort using Shuxuetong injection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
OTHER
China Academy of Chinese Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanming Xie
Deputy Director, Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan M Xie
Role: PRINCIPAL_INVESTIGATOR
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009zx09502-030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.